KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Gross Margin (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Gross Margin data on record, last reported at 96.45% in Q4 2025.

  • For Q4 2025, Gross Margin changed N/A year-over-year to 96.45%; the TTM value through Dec 2025 reached 93.31%, changed N/A, while the annual FY2025 figure was 93.31%, 96.0% up from the prior year.
  • Gross Margin reached 96.45% in Q4 2025 per REGN's latest filing, up from 92.52% in the prior quarter.
  • Across five years, Gross Margin topped out at 301.0% in Q4 2022 and bottomed at 314.6% in Q1 2022.
  • Average Gross Margin over 5 years is 57.21%, with a median of 92.52% recorded in 2025.
  • Peak YoY movement for Gross Margin: plummeted -40736bps in 2022, then surged 40672bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 97.48% in 2021, then surged by 209bps to 301.0% in 2022, then plummeted by -69bps to 93.32% in 2023, then fell by 0bps to 92.95% in 2024, then increased by 4bps to 96.45% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 96.45% in Q4 2025, 92.52% in Q3 2025, and 92.5% in Q2 2025.